Recent studies cover therapeutic and diagnostic advances in oncology. Natera presented improved survival data in Signatera-positive bladder cancer patients receiving Tecentriq, progressing towards FDA companion diagnostic approval. Amgen introduced AMG-410, a pan-KRAS inhibitor targeting multiple KRAS mutations across cancers. Cadonilimab exhibited clinical promise in advanced gynecological cancers, while research identified Sideroflexin 1 as a potential bladder cancer target. Diamond-based magnetic field sensors offer new possibilities for detecting metastatic breast cancer intraoperatively, reflecting broad innovation in cancer diagnosis and therapy.